Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma

Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma is a phase 2 interventional study registered as NCT00390234 by National Cancer Institute (NCI), with 63 participants recorded, started 2006-09 and reaching its primary completion in 2011-09. Interventions recorded: ziv-aflibercept. Conditions recorded: Fallopian Tube Cancer, Female Reproductive Cancer, Ovarian Carcinosarcoma, Ovarian Sarcoma, Recurrent Ovarian Epithelial Cancer, Recurrent Uterine Sarcoma, Stage III Ovarian Epithelial Cancer, Stage III Uterine Sarcoma, Stage IV Ovarian Epithelial Cancer, Stage IV Uterine Sarcoma, Uterine Carcinosarcoma, Uterine Leiomyosarcoma.

Linked to the drug Ziv-aflibercept because the registry names it among its interventions and Ovarian cancer, Uterine sarcoma, Uterine carcinosarcoma and Leiomyosarcoma among its conditions. Registry record only: no result has been read by an editor.